Immune heterogeneity-driven therapeutic responses to platelet-rich plasma and TRPV1 antagonism in osteoarthritis
Pengmin Liu, Jingwei Zhu, Yang Yang, Hailong Kou, Fei Yin, Laifu Yang · 2026
Read Immune heterogeneity-driven therapeutic responses to platelet-rich plasma and TRPV1 antagonism in osteoarthritis by Pengmin Liu, Jingwei Zhu, Yang Yang, Hailong Kou, Fei Yin, Laifu Yang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13590553.txt.
Description
Pengmin Liu and five co-authors study why osteoarthritis pain treatment works unevenly, in a 2026 paper. Joints differ in their immune profile, and that may explain varied responses to standard care. The team tests a combined approach: platelet rich plasma plus a drug that blocks a pain sensing channel called TRPV1.
In rats with induced joint disease, the pair eased pain more than either part alone. It shifted joint immune cells toward a calming type, lowered inflammatory signals, and quieted pain pathways in nerves and the spinal cord. In a group of 140 patients, the combined care also gave better pain relief and function. The authors propose a neuroimmune model for matching treatment to joint profile.
Catalog record
| CREATOR | Pengmin Liu, Jingwei Zhu, Yang Yang, Hailong Kou, Fei Yin, Laifu Yang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |